any holders ..any views ..looks to hve a great potential ...


Alltracel Pharmaceuticals Plc
06 April 2004


Alltracel Releases First Quarter 2004 Trading Update

-- First Quarter Revenue Grew 340% to 857k versus Q1 2003, and Company gives
Guidance for Q2--

-- SEALONTM Commences Marketing Support Programs as mdocTM Co-Brand
Partnership Program Continues to Expand--


April 06, 2004: Dublin, Ireland

Alltracel Pharmaceuticals Plc., (AIM: AP.L), the biopharmaceutical R&D company
specializing in medical devices and compounds and owner of the stops-bleeding m
docTM first-aid ingredient brand and SEALONTM - the consumer first-aid brand
featuring stops-bleeding as standard, is pleased to announce its first quarter
(Q1 2004) revenue was 857k, up 340% over first quarter 2003 revenues and more
than double last quarter's (Q4 2003) record revenue result.

Donal O'Brien Alltracel's Chief Operating Officer (COO) commented:

'As we expected Alltracel had a solid start to this year fuelled by strong SEAL
ONTM shipments in both the USA and UK on the back of last quarters trade listing
agreements and the start of our trade marketing program; as well as by continued
expansion in Europe of the mdocTM co-brand partnership program and the
commencement of shipments to Asia.

In addition to the previously announced co-brand partnership agreements with
retail and proprietary first aid brands across the EU, in this first quarter we
signed up 5 leading first-aid brands in Norway, Austria, Greece, Turkey and the
BeNeLux region to the mdocTM co-brand partnership program. This now brings to
32 to the number of brand partners in the program.

In this quarter we strengthened our global manufacturing capability with the
formal extension of our co-operation with our leading EU manufacturing partner
Chemopharma in the Czech Republic as well as with the appointment of Bangkok
based Neoplast Company Ltd. as our manufacturing and business development
partner for the Asia Pacific region.

Our first order for the Asia Pacific region already shipped in Q1.

To further secure our long term quality manufacturing capability, former
Hewlett-Packard and Loctite manufacturing executive Ciaran O' Reilly was
appointed as head of Manufacturing and Logistics and in this role he is
responsible for all manufacturing, product development, logistics and quality
standards in our own and partner facilities worldwide.

We saw an exciting breakthrough in our product development this quarter with the
successful development of a revolutionary new stops-bleeding product delivery
system - blottersTM. The blottersTM are small, thin, film strips (similar to
breath freshener strips) impregnated with mdocTM Alltracel's unique blood
stopping ingredient and are packed in a convenient pocket-sized plastic
dispenser. When placed on minor cuts e.g. shaving nicks blottersTM dissolve
after a few seconds releasing the mdocTM active ingredient and forming a soft
gel-like layer over the wound to stop the bleeding fast.

SEALONTM blottersTM have already been listed at Boots in the UK and are
expected to ship this quarter (Q2) followed by the introduction of Boots own
brand blottersTMsubsequently.

Our commercial focus this quarter remains on the start-up of SEALONTM consumer
marketing programs as well as further expansion of the mdocTM co-brand
partnership program primarily in the EU and Asia.

We are confident that this quarters revenue figure will be in the 1.0 to 1.2
million range.'

more good news today and 20+% up! holding for over a year now and very hopeful for the future

has ticked up over the past two days. any ideas why

the chinese partnership may lead to massive orders or a larger company may buy alltracell, the market size of china is worth considering also it seems the chinese partner is a much larger company .

The only way is up

Alltracel has two new products Following successful regulatory approval in the EU the company will launch Q4 a new stop bleeding gelthe launch will be made through existing consumer first aid brand leader to the major EU market..

Also new to the product range will be a range of stops bleeding blottersTM known in the trade as thin film first aid grooming products a presentation will be made to potential partners in Q4.

When you have time visit shareclubuk web site and read all the news on AP. The company is gearing up for the next Q to once more increase turnover and profits.

As a matter of interest AP. Has set up a joint venture with Elmarco.. To beef up its wound care business.. The business will focus on the global professional and consumer wound care markets, under the banner Nanopeutics Sro.. Selling the patented NanopsiderTM products..

This came into me by e.mail 30th October,.

Heard on the grapevine that AP are in late stage discussions
with Smith & Nephew and Baxter Healthcare re; the new nanotech wound
dressings - statement before year end.

Any one in the know

Alltracel expects to reveal its strategy for entering the functional foods market with its cellulose fibre bioactive for cholesterol management by the end of this year, as discussions progress with potential partners in the EU, US and Asia.

Dorothy our 65 year old coffee woman informed us at our coffee meeting for shareclubuk that Alltracel & risqus Nanopeutics subsidiary has signed an exclusive partnership agreement with a world wide leader in the professional wound care market The agreement is for an exclusive six month period and is focused on the development of a range of Nan fibre based profession wound care technologies and products

Under the agreement, all development work and associated costs will be paid for by the partner as well as payments agreement undisclosed licence fee for the six months exclusivity period..
Successful development will lead to exclusive global royalty bearing licence and supply agreement for Nanospiderr TM based technology and specialist products for the professional wound care and potential related markets

Outside of this significant development for the professional markets, Nanopeutics TM is now in discussions with a number of other wound care companies for consumer wound care and other applications Can any one let me know of the latest brokers report on AP. . ?

Our shareclubuk meeting this morning was set up for a talk on Alltracel PH Plc

I know that a lot of you know about the successful development of a highly soluble derivative of AP. patented cardiovascular health benefiting bioactive. However for those reader of this message board who do not know the breakthrough in Tisnow, Czech Republic for the company can lead to an entry into the functional beverage industry.. Which is by far the most innovative and profitable sector within the functional food and nutritional marketplace..

I noticed that the company has reported that the big boys are now taking an interest Alltracel has received a notification from AXA Investment Managers UK Ltd. dated 30 November 2006, stating that, following an acquisition of shares, Framlington HSBC was the registered holder of a non-beneficial interest in 12,000,000 ordinary shares, representing approximately 9.26% of the issued ordinary share capital of Alltracel.

Where's AP. gone today?

AP.s. share price has started to move up over the last few weeks at the close of the markets last night it stood at 11.75p. Nanopeutics signs exclusive technology agreement with HemCon Medical Technologies, Inc. for Military market read the full report at www.shareclubuk.co.uk

Helium Special Situations Fund is now interested in 4,000,000 ordinary shares of the Company, representing 3.08 per cent. of the Company's issued share capital brewing up..

their pipeline is very strong, wound care is cost sensitive, CVS is the big thing they are entering and being courted, price has bottomed out, results mid April will beat analysts expectations - buy buy

The US army is now a major client and the US and China markets are staring to open up.
Results in April should start the next upturn

FfastFill is continuing to engage with and sign up new customers, such as the
contract with Natexis Commodity Markets which was announced on 27 February 2007, and New client win 30 March FFastFill signs Calyon Financial for its Application Service. This should be the fist step of many that will move the company forward. Full report can be found at shareclubuk its well worth reading as more good news and background on the company.

Out today the Alltracel 2006 Full Year Preliminary Results. As a share holder I am pleased to read about the turnaround in profitability with a first time full year positive EBITDA of euro;1.2M versus a loss of euro;1.1M in 2005. There as also been significant growth in gross margin percentage up 4 points to 39% driven by the commencement of first technology license revenue in the final quarter

The products show improvements all round with continued strong oral care trade performance with business wins in all major markets and advanced discussions on potential M&A activity. Successful development and commercialisation of patented Nanofibre technology and securing of first license revenue via Nanopeutics subsidiary. Significant technological and commercial progress on proprietary PAGA science leading to new market entry in CVH and Cosmeceuticals markets in 2007.

The next six months should show a stonger turn-round for Alltracel. The full report has been posted at shareclubuk. At long last I am showing a small profit on the Investment.

Alltracel Pharmaceuticals Plc., Tony Richardson, Chief Executive Officer of the Company, acquired 150,000 ordinary shares of euro;0.0125 each ("Ordinary Shares") on 17 April 2007. The Ordinary Shares were bought at pound;0.12 p each and following this acquisition, Mr Richardson now holds a total of 1,885,306 Ordinary Shares, which represents approximately 1.36 per cent of the Company's issued share capital.

The company share price has been moving up over the last few days. Full details on the company can be found at shareclubuk.co.uk The above news is just what I like to see as a share holder myself, Tony Richardson has faith in his own business a commitment that speaks volumes.

Noel Toolan, Chief Marketing Officer of Alltracel Pharmaceuticals Plc., has acquired 150,000 ordinary shares of euro;0.0125 each ("Ordinary Shares") on the 24 April 2007. The Ordinary Shares were bought at pound;0.135 p each and following this acquisition, Mr Toolan now holds a total of 150,000 Ordinary Shares, which represents approximately 0.115 per cent of the Company's issued share capital. Find out more at shareclubuk.co.uk.

This follows an announcement last week that Chief Executive Officer, Tony Richardson had acquired 150,000 shares in the company, he now holds 1,885,306 Ordinary Shares 1.36%.

Alltracel is set to enter the very lucrative international cosmenceuticals marketplace with their new product PhytopeuticsTM technology brand. My Wife and her friends spend a small fortune on skin care, I know this is a fact as I can just about find my after shave in the midst of all the skin repair kit, or polly-filler as I call them. Todays news is indeed first class, representing new sales area for the new sikn care proven product. The full report and other news on the company can be found at shareclubuk.co.uk.

Mr. Nick Hart joins AP. as CFO and executive director. Jan Dublin.
Your Say at shareclubuk.co,uk New product have to be marketed.